Title
Dose painting in radiotherapy for head and neck squamous cell carcinoma : value of repeated functional imaging with <tex>$^{18}F-FDG$</tex> PET, <tex>$^{18}F$</tex>-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI Dose painting in radiotherapy for head and neck squamous cell carcinoma : value of repeated functional imaging with <tex>$^{18}F-FDG$</tex> PET, <tex>$^{18}F$</tex>-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Publication type
article
Publication
New York ,
Subject
Human medicine
Source (journal)
The Journal of nuclear medicine. - New York
Volume/pages
50(2009) :7 , p. 1020-1027
ISSN
0161-5505
ISI
000272547100010
Carrier
E
Target language
English (eng)
Full text (Publishers DOI)
Abstract
The purpose of this work was to evaluate the potential of functional imaging with 18F-FDG PET, 18F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI to provide an appropriate and reliable biologic target for dose painting in radiotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Fifteen patients with locally advanced HNSCC, treated with concomitant chemoradiotherapy, were prospectively enrolled in a bioimaging protocol. Sequential PET (18F-FDG and 18F-fluoromisonidazole) and MRI (T1, T2, dynamic enhanced, and diffusion-weighted sequences) were performed before, during, and after radiotherapy. Results: Median follow-up was 30.7 mo (range, 6.356.3 mo); in 7 patients, disease recurred. Disease-free survival correlated negatively with the maximum tissue-to-blood 18F-fluoromisonidazole ratio (T/Bmax) on the baseline 18F-fluoromisonidazole scan (P = 0.04), with the size of the initial hypoxic volume (P = 0.04), and with T/Bmax on the 18F-fluoromisonidazole scan during treatment (P = 0.02). All locoregional recurrences were within the 18F-FDGavid regions on baseline 18F-FDG PET; 3 recurrences mapped outside the hypoxic volume on baseline 18F-fluoromisonidazole PET. Lesions (primary tumor and lymph nodes) where a locoregional recurrence developed during follow-up had significantly lower apparent diffusion coefficients on diffusion-weighted MRI during week 4 of radiotherapy (0.0013 vs. 0.0018 mm2/s, P = 0.01) and at 3 wk after treatment (0.0014 vs. 0.0018 mm2/s, P = 0.01) and a significantly higher initial slope on baseline dynamic enhanced MRI (26.2 vs. 17.5/s, P = 0.03) than did lesions that remained controlled. Conclusion: These results confirm the added value of 18F-FDG PET and 18F-fluoromisonidazole PET for radiotherapy planning of HNSCC and suggest the potential of diffusion-weighted and dynamic enhanced MRI for dose painting and early response assessment.
E-info
https://repository.uantwerpen.be/docman/iruaauth/cc0376/738a31dba9c.pdf
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000272547100010&DestLinkType=RelatedRecords&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000272547100010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000272547100010&DestLinkType=CitingArticles&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848